Solubilization and preformulation studies on PG-300995 (an anti-HIV drug)

Yingqing Ran, Akash Jain, Samuel H Yalkowsky

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This study investigates the solubilization of a potential anti-human immunodeficiency virus agent [PG-300995 or 2-(2-thiophenyl)-4-azabenzoimidazole] for oral administration. The intrinsic solubility of PG-300995 is 51 μg/mL. Multiple approaches including combinations of pH control and cosolvency, micellization, or complexation were used to improve the solubility of PG-300995. The combined techniques increased the solubility of both the unionized and ionized species. The solubility of the drug increased from 20 to 200 times depending on the pH and concentration of solubilization agents. The following formulations which contain the desired doses of 5 and 10 mg/mL were developed for oral administration. Formulation A: 10 mg/mL PG-300995 in 20% sulfobutyl ether-β-cyclodextrin at pH 2; formulations B: 5 mg/mL PG-300995 in 10% sulfobutyl ether-β-cyclodextrin at pH 2; formulation C: 5 mg/mL PG-300995 in 10% ethanol+40% propylene glycol at pH 2. No precipitation was observed after series dilution of these three formulations with water or pH 2 buffers. These formulations are stable for at least 6 months after storing at room temperature and 37°C.

Original languageEnglish (US)
Pages (from-to)297-303
Number of pages7
JournalJournal of Pharmaceutical Sciences
Volume94
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Anti-HIV Agents
Solubility
Cyclodextrins
Ether
Propylene Glycol
Micellization
Oral Administration
Complexation
Viruses
Dilution
Buffers
Ethanol
Water
HIV
Pharmaceutical Preparations
Temperature

Keywords

  • PG-300995
  • Preformulation
  • Solubilization

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

Solubilization and preformulation studies on PG-300995 (an anti-HIV drug). / Ran, Yingqing; Jain, Akash; Yalkowsky, Samuel H.

In: Journal of Pharmaceutical Sciences, Vol. 94, No. 2, 02.2005, p. 297-303.

Research output: Contribution to journalArticle

@article{b149d107f4f74a719410d2e351c81177,
title = "Solubilization and preformulation studies on PG-300995 (an anti-HIV drug)",
abstract = "This study investigates the solubilization of a potential anti-human immunodeficiency virus agent [PG-300995 or 2-(2-thiophenyl)-4-azabenzoimidazole] for oral administration. The intrinsic solubility of PG-300995 is 51 μg/mL. Multiple approaches including combinations of pH control and cosolvency, micellization, or complexation were used to improve the solubility of PG-300995. The combined techniques increased the solubility of both the unionized and ionized species. The solubility of the drug increased from 20 to 200 times depending on the pH and concentration of solubilization agents. The following formulations which contain the desired doses of 5 and 10 mg/mL were developed for oral administration. Formulation A: 10 mg/mL PG-300995 in 20{\%} sulfobutyl ether-β-cyclodextrin at pH 2; formulations B: 5 mg/mL PG-300995 in 10{\%} sulfobutyl ether-β-cyclodextrin at pH 2; formulation C: 5 mg/mL PG-300995 in 10{\%} ethanol+40{\%} propylene glycol at pH 2. No precipitation was observed after series dilution of these three formulations with water or pH 2 buffers. These formulations are stable for at least 6 months after storing at room temperature and 37°C.",
keywords = "PG-300995, Preformulation, Solubilization",
author = "Yingqing Ran and Akash Jain and Yalkowsky, {Samuel H}",
year = "2005",
month = "2",
doi = "10.1002/jps.20246",
language = "English (US)",
volume = "94",
pages = "297--303",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Solubilization and preformulation studies on PG-300995 (an anti-HIV drug)

AU - Ran, Yingqing

AU - Jain, Akash

AU - Yalkowsky, Samuel H

PY - 2005/2

Y1 - 2005/2

N2 - This study investigates the solubilization of a potential anti-human immunodeficiency virus agent [PG-300995 or 2-(2-thiophenyl)-4-azabenzoimidazole] for oral administration. The intrinsic solubility of PG-300995 is 51 μg/mL. Multiple approaches including combinations of pH control and cosolvency, micellization, or complexation were used to improve the solubility of PG-300995. The combined techniques increased the solubility of both the unionized and ionized species. The solubility of the drug increased from 20 to 200 times depending on the pH and concentration of solubilization agents. The following formulations which contain the desired doses of 5 and 10 mg/mL were developed for oral administration. Formulation A: 10 mg/mL PG-300995 in 20% sulfobutyl ether-β-cyclodextrin at pH 2; formulations B: 5 mg/mL PG-300995 in 10% sulfobutyl ether-β-cyclodextrin at pH 2; formulation C: 5 mg/mL PG-300995 in 10% ethanol+40% propylene glycol at pH 2. No precipitation was observed after series dilution of these three formulations with water or pH 2 buffers. These formulations are stable for at least 6 months after storing at room temperature and 37°C.

AB - This study investigates the solubilization of a potential anti-human immunodeficiency virus agent [PG-300995 or 2-(2-thiophenyl)-4-azabenzoimidazole] for oral administration. The intrinsic solubility of PG-300995 is 51 μg/mL. Multiple approaches including combinations of pH control and cosolvency, micellization, or complexation were used to improve the solubility of PG-300995. The combined techniques increased the solubility of both the unionized and ionized species. The solubility of the drug increased from 20 to 200 times depending on the pH and concentration of solubilization agents. The following formulations which contain the desired doses of 5 and 10 mg/mL were developed for oral administration. Formulation A: 10 mg/mL PG-300995 in 20% sulfobutyl ether-β-cyclodextrin at pH 2; formulations B: 5 mg/mL PG-300995 in 10% sulfobutyl ether-β-cyclodextrin at pH 2; formulation C: 5 mg/mL PG-300995 in 10% ethanol+40% propylene glycol at pH 2. No precipitation was observed after series dilution of these three formulations with water or pH 2 buffers. These formulations are stable for at least 6 months after storing at room temperature and 37°C.

KW - PG-300995

KW - Preformulation

KW - Solubilization

UR - http://www.scopus.com/inward/record.url?scp=14344251899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14344251899&partnerID=8YFLogxK

U2 - 10.1002/jps.20246

DO - 10.1002/jps.20246

M3 - Article

VL - 94

SP - 297

EP - 303

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 2

ER -